SMER 28enhancer of the cytostatic effects CAS# 307538-42-7 |
- BV6
Catalog No.:BCC5372
CAS No.:1001600-56-1
- LCL161
Catalog No.:BCC1691
CAS No.:1005342-46-0
- Birinapant (TL32711)
Catalog No.:BCC2250
CAS No.:1260251-31-7
- Embelin
Catalog No.:BCN2678
CAS No.:550-24-3
- GDC-0152
Catalog No.:BCC2252
CAS No.:873652-48-3
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 307538-42-7 | SDF | Download SDF |
PubChem ID | 1560402 | Appearance | Powder |
Formula | C11H10BrN3 | M.Wt | 264.12 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : ≥ 32 mg/mL (121.16 mM) *"≥" means soluble, but saturation unknown. | ||
Chemical Name | 6-bromo-N-prop-2-enylquinazolin-4-amine | ||
SMILES | C=CCNC1=NC=NC2=C1C=C(C=C2)Br | ||
Standard InChIKey | BCPOLXUSCUFDGE-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C11H10BrN3/c1-2-5-13-11-9-6-8(12)3-4-10(9)14-7-15-11/h2-4,6-7H,1,5H2,(H,13,14,15) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Positive regulator of autophagy in a mechanism independent from the mTOR pathway. Increases autophagosome synthesis and enhances clearance of model autophagy substrates such as mutant huntingtin and A53T α-synuclein, associated with Huntington's and Parkinson's diseases, respectively. Promotes reprogramming of fibroblasts to neural stem-like cells in combination with other chemical reagents. |
SMER 28 Dilution Calculator
SMER 28 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.7862 mL | 18.9308 mL | 37.8616 mL | 75.7232 mL | 94.6539 mL |
5 mM | 0.7572 mL | 3.7862 mL | 7.5723 mL | 15.1446 mL | 18.9308 mL |
10 mM | 0.3786 mL | 1.8931 mL | 3.7862 mL | 7.5723 mL | 9.4654 mL |
50 mM | 0.0757 mL | 0.3786 mL | 0.7572 mL | 1.5145 mL | 1.8931 mL |
100 mM | 0.0379 mL | 0.1893 mL | 0.3786 mL | 0.7572 mL | 0.9465 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
IC50: N/A
SMER 28 is a new small-molecule enhancer of the cytostatic effects. The target of rapamycin proteins has been reported to be able to regulate various cellular processes including autophagy, which may play a protective role in some neurodegenerative and infectious diseases.
In vitro: SMER 28 independently induced autophagy of rapamycin in mammalian cells, enhancing the clearance of autophagy substrates such as A53T a-synuclein and mutant huntingtin, which were associated with Huntington’s and Parkinson’s disease. SMER 28, which seemed to act either independently or downstream of the rapamycin target, was found to attenuate the mutant huntingtin-fragment toxicity in Huntington’s disease cells [1].
In vivo: Previous study confirmed that the reduction of EGFP-HDQ74 aggregation occured through autophagy using autophagy-competent mouse embryonic fibroblasts (MEFs) (Atg5+/+). EGFP-HDQ74 aggregation was increased significantly in untreated Atg5-/- (autophagy-deficient) cells when compared with untreated Atg5+/+ cells. SMER 28 reduced EGFP-HDQ74 aggregation in Atg5+/+ cells significantly, but not in Atg5-/- cells). Therefore, SMER 28 could only reduce mutant huntingtin aggregation in autophagy-competent cells [1].
Clinical trial: N/A
Reference:
[1] Sarkar S,Perlstein EO,Imarisio S,Pineau S,Cordenier A,Maglathlin RL,Webster JA,Lewis TA,O'Kane CJ,Schreiber SL,Rubinsztein DC. Small molecules enhance autophagy and reduce toxicity in Huntington's disease models. Nat Chem Biol.2007 Jun;3(6):331-8.
- CFTRinh-172
Catalog No.:BCC4419
CAS No.:307510-92-5
- Troxipide
Catalog No.:BCC4744
CAS No.:30751-05-4
- 1,4-Bis[2-(4-methyl-5-phenyloxazolyl)]benzene
Catalog No.:BCC8425
CAS No.:3073-87-8
- WAY 170523
Catalog No.:BCC2380
CAS No.:307002-73-9
- CL 82198 hydrochloride
Catalog No.:BCC2372
CAS No.:307002-71-7
- GW-1100
Catalog No.:BCC1610
CAS No.:306974-70-9
- IBC 293
Catalog No.:BCC7376
CAS No.:306935-41-1
- TCID
Catalog No.:BCC4449
CAS No.:30675-13-9
- 5-Methoxy-7-hydroxycoumarin
Catalog No.:BCN3538
CAS No.:3067-10-5
- Cycloolivil
Catalog No.:BCN4081
CAS No.:3064-05-9
- (20S)-Protopanaxdiol
Catalog No.:BCN1254
CAS No.:30636-90-9
- AVE 0991 sodium salt
Catalog No.:BCC4222
CAS No.:306288-04-0
- STF 083010
Catalog No.:BCC6209
CAS No.:307543-71-1
- Crosemperine
Catalog No.:BCN2074
CAS No.:30785-56-9
- [Des-octanoyl]-Ghrelin (rat)
Catalog No.:BCC5953
CAS No.:307950-60-3
- beta-Anhydrouzarigenin
Catalog No.:BCN5222
CAS No.:3080-20-4
- L-Theanine
Catalog No.:BCN2571
CAS No.:3081-61-6
- AEBSF.HCl
Catalog No.:BCC1219
CAS No.:30827-99-7
- 4-Oxododecanedioic acid
Catalog No.:BCN5223
CAS No.:30828-09-2
- Spongouridine
Catalog No.:BCC9152
CAS No.:3083-77-0
- PM00104
Catalog No.:BCC4237
CAS No.:308359-57-1
- Aloesin
Catalog No.:BCN8437
CAS No.:30861-27-9
- Kauran-18-Olc Acid,16,1719-Tnhydroxy-,(4A)
Catalog No.:BCC9235
CAS No.:308821-59-2
- 8-Epixanthatin
Catalog No.:BCN7782
CAS No.:30890-35-8
Pharmacological Reprogramming of Fibroblasts into Neural Stem Cells by Signaling-Directed Transcriptional Activation.[Pubmed:27133794]
Cell Stem Cell. 2016 May 5;18(5):653-67.
Cellular reprogramming using chemically defined conditions, without genetic manipulation, is a promising approach for generating clinically relevant cell types for regenerative medicine and drug discovery. However, small-molecule approaches for inducing lineage-specific stem cells from somatic cells across lineage boundaries have been challenging. Here, we report highly efficient reprogramming of mouse fibroblasts into induced neural stem cell-like cells (ciNSLCs) using a cocktail of nine components (M9). The resulting ciNSLCs closely resemble primary neural stem cells molecularly and functionally. Transcriptome analysis revealed that M9 induces a gradual and specific conversion of fibroblasts toward a neural fate. During reprogramming specific transcription factors such as Elk1 and Gli2 that are downstream of M9-induced signaling pathways bind and activate endogenous master neural genes to specify neural identity. Our study provides an effective chemical approach for generating neural stem cells from mouse fibroblasts and reveals mechanistic insights into underlying reprogramming processes.
Chemical inducers of autophagy that enhance the clearance of mutant proteins in neurodegenerative diseases.[Pubmed:20147746]
J Biol Chem. 2010 Apr 9;285(15):11061-7.
Many of the neurodegenerative diseases that afflict people are caused by intracytoplasmic aggregate-prone proteins. These include Parkinson disease, tauopathies, and polyglutamine expansion diseases such as Huntington disease. In Mendelian forms of these diseases, the mutations generally confer toxic novel functions on the relevant proteins. Thus, one potential strategy for dealing with these mutant proteins is to enhance their degradation. This can be achieved by up-regulating macroautophagy, which we will henceforth call autophagy. In this minireview, we will consider the reasons why autophagy up-regulation may be a powerful strategy for these diseases. In addition, we will consider some of the drugs and associated signaling pathways that can be used to induce autophagy with these therapeutic aims in mind.
Small molecules enhance autophagy and reduce toxicity in Huntington's disease models.[Pubmed:17486044]
Nat Chem Biol. 2007 Jun;3(6):331-8.
The target of rapamycin proteins regulate various cellular processes including autophagy, which may play a protective role in certain neurodegenerative and infectious diseases. Here we show that a primary small-molecule screen in yeast yields novel small-molecule modulators of mammalian autophagy. We first identified new small-molecule enhancers (SMER) and inhibitors (SMIR) of the cytostatic effects of rapamycin in Saccharomyces cerevisiae. Three SMERs induced autophagy independently of rapamycin in mammalian cells, enhancing the clearance of autophagy substrates such as mutant huntingtin and A53T alpha-synuclein, which are associated with Huntington's disease and familial Parkinson's disease, respectively. These SMERs, which seem to act either independently or downstream of the target of rapamycin, attenuated mutant huntingtin-fragment toxicity in Huntington's disease cell and Drosophila melanogaster models, which suggests therapeutic potential. We also screened structural analogs of these SMERs and identified additional candidate drugs that enhanced autophagy substrate clearance. Thus, we have demonstrated proof of principle for a new approach for discovery of small-molecule modulators of mammalian autophagy.